Valeo (0RH5) Share Forecast & Price Target
0RH5 Analyst Ratings
0RH5 Stock 12 Month Forecast
Average Price Target
EUR 13.64▲(22.51% Upside)Detailed List of Analyst Forecasts
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Christoph Laskawi | Deutsche Bank | EUR 13→EUR 11 | hold | -1.17%Downside | Reiterated | 10/27/26 | ||
| Ross MacDonald | Citi | EUR 14.60→EUR 13.50 | hold | 21.29%Upside | Reiterated | 10/27/26 | ||
| Romain Gourvil | Berenberg Bank | EUR 15→EUR 14 | buy | 25.79%Upside | Reiterated | 10/26/26 | ||
| Chris McNally | Evercore ISI | EUR 15→EUR 12 | hold | 7.82%Upside | Downgraded | 10/26/26 | ||
| Javier Martinez Olcoz Cerdan | Morgan Stanley | EUR 14.10 | buy | 26.68%Upside | Reiterated | 10/19/26 | ||
| Patrick Hummel | UBS | EUR 13 | hold | 16.80%Upside | Reiterated | 10/09/26 | ||
| Vanessa Jeffriess | Jefferies | EUR 17.85 | buy | 60.38%Upside | Reiterated | 10/07/26 | ||
| Stephen Reitman | Bernstein | EUR 13→EUR 15 | hold | 34.77%Upside | Reiterated | 07/23/26 | ||
| Thomas Besson | Kepler Capital | EUR 9→EUR 10 | sell | -10.15%Downside | Reiterated | 06/22/26 | ||
| Jose Asumendi | J.P. Morgan | EUR 22 | buy | 97.66%Upside | Reiterated | 06/08/26 | ||
| Erwann Dagorne | Barclays | EUR 11 | hold | -1.17%Downside | Reiterated | 04/14/26 | ||
| Elizabelle Pang | DBS | EUR 11 | hold | -1.17%Downside | Reiterated | 03/27/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Christoph Laskawi | 10/27/26 | EUR 13→EUR 11 | hold | -1.17%Downside | Reiterated | Deutsche Bank | ||
| Ross MacDonald | 10/27/26 | EUR 14.60→EUR 13.50 | hold | 21.29%Upside | Reiterated | Citi | ||
| Romain Gourvil | 10/26/26 | EUR 15→EUR 14 | buy | 25.79%Upside | Reiterated | Berenberg Bank | ||
| Chris McNally | 10/26/26 | EUR 15→EUR 12 | hold | 7.82%Upside | Downgraded | Evercore ISI | ||
| Javier Martinez Olcoz Cerdan | 10/19/26 | EUR 14.10 | buy | 26.68%Upside | Reiterated | Morgan Stanley | ||
| Patrick Hummel | 10/09/26 | EUR 13 | hold | 16.80%Upside | Reiterated | UBS | ||
| Vanessa Jeffriess | 10/07/26 | EUR 17.85 | buy | 60.38%Upside | Reiterated | Jefferies | ||
| Stephen Reitman | 07/23/26 | EUR 13→EUR 15 | hold | 34.77%Upside | Reiterated | Bernstein | ||
| Thomas Besson | 06/22/26 | EUR 9→EUR 10 | sell | -10.15%Downside | Reiterated | Kepler Capital | ||
| Jose Asumendi | 06/08/26 | EUR 22 | buy | 97.66%Upside | Reiterated | J.P. Morgan | ||
| Erwann Dagorne | 04/14/26 | EUR 11 | hold | -1.17%Downside | Reiterated | Barclays | ||
| Elizabelle Pang | 03/27/26 | EUR 11 | hold | -1.17%Downside | Reiterated | DBS |
Best Analysts Covering Valeo
Copying Romain Gourvil's trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +2.78% per trade.
Copying Thomas Besson's trades and holding each position for 1 Year would result in 34.48% of your transactions generating a profit, with an average return of -12.04% per trade.
Copying Jose Asumendi's trades and holding each position for 2 Years would result in 33.33% of your transactions generating a profit, with an average return of -12.03% per trade.
0RH5 Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 1 | 0 | 0 | 0 | 0 |
| Buy | 2 | 5 | 6 | 5 | 5 |
| Hold | 7 | 4 | 5 | 3 | 5 |
| Sell | 4 | 1 | 1 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 14 | 10 | 12 | 8 | 10 |
In the current month, 0RH5 has received 5 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. 0RH5 average Analyst price target in the past 3 months is 13.64.
0RH5 Financial Forecast
0RH5 Earnings Forecast
Next quarter’s earnings estimate for 0RH5 is EUR 0.37 with a range of EUR 0.37 to EUR 0.37. The previous quarter’s EPS was EUR 0.26. Its overall industry beat the EPS estimate 50.49% of the time in the past 12 months.
0RH5 Sales Forecast
Next quarter’s sales forecast for 0RH5 is EUR 5.09B with a range of EUR 5.09B to EUR 5.09B. The previous quarter’s sales results were EUR 10.38B. Its overall industry beat sales estimates 63.25% of the time in the past 12 months.